Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $55 Price Target

Travere Therapeutics, Inc.

Travere Therapeutics, Inc.

TVTX

0.00

Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ: TVTX) with a Outperform and maintains $55 price target.